NIS study determining prevalence of HER2-low in metastatic breast cancer patients - iRetroBC

Study identifier:D9673R00037

ClinicalTrials.gov identifier:NCT06131424

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Multicentre NIS retrospective study to know the prevalence of HER2- low,clinical characteristics,treatment patterns,associated outcome in patient with HER2-negative in metastatic breast cancer who progressed on systemic anticancer therapy

Medical condition

HER2-negative

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

2700

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 23 Apr 2024
Estimated Primary Completion Date: 30 Sept 2025
Estimated Study Completion Date: 30 Sept 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria